HUP0202508A2 - Method of inhibiting amyloid protein aggregation and imaging amyloid deposits - Google Patents
Method of inhibiting amyloid protein aggregation and imaging amyloid depositsInfo
- Publication number
- HUP0202508A2 HUP0202508A2 HU0202508A HUP0202508A HUP0202508A2 HU P0202508 A2 HUP0202508 A2 HU P0202508A2 HU 0202508 A HU0202508 A HU 0202508A HU P0202508 A HUP0202508 A HU P0202508A HU P0202508 A2 HUP0202508 A2 HU P0202508A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- atom
- protein aggregation
- phenyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title abstract 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 230000004845 protein aggregation Effects 0.000 title abstract 3
- 208000037259 Amyloid Plaque Diseases 0.000 title abstract 2
- 238000003384 imaging method Methods 0.000 title 1
- -1 hydroxy, amino group Chemical group 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005504 styryl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
- C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/62—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino groups and at least two carboxyl groups bound to carbon atoms of the same six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A találmány amiloid protein aggregáció gátlására és amiloidlerakódások kimutatására szolgáló eljárásokra, az eljárásokbanalkalmazható (I) általános képletű vegyületek - amelyeknek képletébenRa jelentése hidrogénatom, 1-6 szénatomos alkilcsoport vagy (1-6szénatomos alkil)-karbonil-csoport; n értéke 0, 1, 2, 3, 4 vagy 5; R1,R2, R3, R4, R5, R6 és R7 jelentése egymástól függetlenül hidrogén-,halogénatom, hidroxi-, aminocsoport, -NRbRc általános képletű csoport,karboxicsoport, (1-6 szénatomos alkoxi)-karbonil-csoport,nitrocsoport, 1-12 szénatomos alkoxicsoport, 1-8 szénatomosalkilcsoport, trifluor-metil-, ciano-, adott esetben szubsztituáltbenzil-oxi-csoport, fenil-(CH2)m- általános képletű csoport, adottesetben szubsztituált fenoxicsoport, sztirilcsoport, -O(CH2)p-NRbRc, -CONRbRc, -NHCORb, -NH(CH2)pNRbRc, -N(1-6 szénatomos alkil) (CH2)pNRbRcáltalános képletű csoport vagy 1,3-bisz(1-6 szénatomos alkoxi)-2-propil-csoport; R8 jelentése karboxi-, tetrazolilcsoport, -SO2Rd vagy-CONH-SO2Rd általános képletű csoport; Rb és Rc jelentése egymástólfüggetlenül hidrogénatom, 1-6 szénatomos alkilcsoport, fenil-(CH2)m-általános képletű csoport, vagy Rb és Rc azzal a nitrogénatommalegyütt, amelyhez a két szubsztituens kapcsolódik, egy ciklusospiperidil-, pirrolil-, imidazolil-, piperazinil-, 4-(1-6 szénatomosalkil)-piperazinil-, morfolino-, tiomorfolino-,dekahidroizokinolilvagy pirazolilcsoportot képez; Rd jelentésehidrogénatom, 1-6 szénatomos alkilcsoport, trifluor-metil- vagyfenilcsoport; m értéke 0, 1, 2, 3, 4 vagy 5; p értéke 1, 2, 3, 4 vagy5; A jelentése metincsoport vagy nitrogénatom; valamint R1 és R2metilén-dioxi-csoportot is jelenthet, ha a két szubsztituens egymássalszomszédos helyzetben van < és gyógyászatilag elfogadható sóikra,valamint a vegyületeket tartalmazó gyógyszerkészítményekre vonatkozik.A találmány szerinti, az amiloid protein aggregáció gátlására szolgálóeljárást az Alzheimer-kór kezelésére alkalmazzák. ÓFor the methods of inhibiting amyloid protein aggregation and detecting amyloid deposits of the invention, the compounds of general formula (I) can be used in the methods - in the formula Ra is a hydrogen atom, a C1-C6 alkyl group or (C1-C6 alkyl)-carbonyl group; n is 0, 1, 2, 3, 4 or 5; R1, R2, R3, R4, R5, R6 and R7 are independently hydrogen, halogen atom, hydroxy, amino group, -NRbRc group, carboxyl group, (C1-C6 alkoxy)carbonyl group, nitro group, 1- 12-carbon alkoxy group, 1-8 carbon-atom alkyl group, trifluoromethyl-, cyano-, optionally substituted benzyloxy group, phenyl(CH2)m- group, optionally substituted phenoxy group, styryl group, -O(CH2)p-NRbRc , -CONRbRc, -NHCORb, -NH(CH2)pNRbRc, -N(C1-C6 alkyl) (CH2)pNRbR group of general formula or 1,3-bis(C1-C6 alkoxy)-2-propyl group; R8 is carboxy, tetrazolyl, -SO2Rd or -CONH-SO2Rd; Rb and Rc independently represent a hydrogen atom, an alkyl group with 1-6 carbon atoms, a group of the general formula phenyl-(CH2)m-, or Rb and Rc together with the nitrogen atom to which the two substituents are attached, a cyclic piperidyl-, pyrrolyl-, imidazolyl-, piperazinyl- , forms a 4-(C1-C6 alkyl)piperazinyl, morpholino, thiomorpholino, decahydroisoquinolyl or pyrazolyl group; Rd represents a hydrogen atom, an alkyl group with 1 to 6 carbon atoms, a trifluoromethyl or a phenyl group; m is 0, 1, 2, 3, 4 or 5; p is 1, 2, 3, 4 or 5; A is a methine group or a nitrogen atom; and R1 and R2 can also be methylenedioxy groups if the two substituents are in adjacent positions < and applies to their medicinally acceptable salts as well as pharmaceutical preparations containing the compounds. The method for inhibiting amyloid protein aggregation according to the invention is used for the treatment of Alzheimer's disease. HE
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13855099P | 1999-06-10 | 1999-06-10 | |
PCT/US2000/015071 WO2000076489A2 (en) | 1999-06-10 | 2000-05-31 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0202508A2 true HUP0202508A2 (en) | 2002-12-28 |
HUP0202508A3 HUP0202508A3 (en) | 2003-03-28 |
Family
ID=22482537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0202508A HUP0202508A3 (en) | 1999-06-10 | 2000-05-31 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP1225886A2 (en) |
JP (1) | JP2003504310A (en) |
KR (1) | KR20020008224A (en) |
CN (1) | CN1378446A (en) |
AP (1) | AP2002002387A0 (en) |
AU (1) | AU775157B2 (en) |
BG (1) | BG106293A (en) |
BR (1) | BR0011728A (en) |
CA (1) | CA2375551A1 (en) |
CR (1) | CR6528A (en) |
DZ (1) | DZ3252A1 (en) |
EA (1) | EA004632B1 (en) |
EE (1) | EE200100673A (en) |
GE (1) | GEP20053423B (en) |
HK (1) | HK1048258A1 (en) |
HR (1) | HRP20020026A2 (en) |
HU (1) | HUP0202508A3 (en) |
IL (1) | IL146971A0 (en) |
IS (1) | IS6193A (en) |
MA (1) | MA26805A1 (en) |
MX (1) | MXPA01012318A (en) |
NO (1) | NO20015995L (en) |
NZ (1) | NZ515621A (en) |
OA (1) | OA11963A (en) |
PL (1) | PL352430A1 (en) |
SK (1) | SK17632001A3 (en) |
TR (1) | TR200103551T2 (en) |
WO (1) | WO2000076489A2 (en) |
YU (1) | YU86701A (en) |
ZA (1) | ZA200109794B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001239544A1 (en) * | 2000-03-22 | 2001-10-03 | Bf Research Institute, Inc. | Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same |
CA2357450A1 (en) * | 2000-09-29 | 2002-03-29 | Warner-Lambert Company | Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis |
GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
ES2327372B1 (en) * | 2007-04-23 | 2010-08-24 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF THE AMINO-NICOTINIC AND AMINO-ISONICOTINIC ACIDS. |
ES2319596B1 (en) * | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF THE AMINO-NICOTINIC AND AMINO-ISONICOTINIC ACIDS. |
JP2010518064A (en) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Piperazine derivatives for the treatment of AD and related conditions |
US20080253967A1 (en) * | 2007-04-13 | 2008-10-16 | Kung Hank F | Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques |
UY31272A1 (en) | 2007-08-10 | 2009-01-30 | Almirall Lab | NEW DERIVATIVES OF AZABIFENILAMINOBENZOIC ACID |
EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
NZ591896A (en) * | 2008-08-29 | 2013-03-28 | Treventis Corp | Compositions and methods of treating amyloid disease |
EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
EP2228367A1 (en) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
EP2536405A1 (en) | 2010-02-16 | 2012-12-26 | Universita Degli Studi di Siena | Non peptidic 14-3-3 inhibitors and the use thereof |
KR20130115311A (en) * | 2010-11-24 | 2013-10-21 | 알러간, 인코포레이티드 | Modulators of s1p receptors |
CN108524482B (en) * | 2017-03-02 | 2022-11-25 | 中国科学院上海药物研究所 | Use of 2- (substituted phenylamino) benzoic acid FTO inhibitors for treating leukemia |
EP3680232A4 (en) * | 2017-08-07 | 2021-08-11 | Hiroshima University | NOVEL ANTHRANILIC ACID-BASED COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5739169A (en) * | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
HUP0201586A2 (en) * | 1999-06-10 | 2002-08-28 | Warner Lambert Co | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives |
-
2000
- 2000-05-31 TR TR2001/03551T patent/TR200103551T2/en unknown
- 2000-05-31 CN CN00808672A patent/CN1378446A/en active Pending
- 2000-05-31 IL IL14697100A patent/IL146971A0/en unknown
- 2000-05-31 EP EP00939471A patent/EP1225886A2/en not_active Withdrawn
- 2000-05-31 NZ NZ515621A patent/NZ515621A/en unknown
- 2000-05-31 WO PCT/US2000/015071 patent/WO2000076489A2/en not_active Application Discontinuation
- 2000-05-31 YU YU86701A patent/YU86701A/en unknown
- 2000-05-31 GE GE4687A patent/GEP20053423B/en unknown
- 2000-05-31 EA EA200101135A patent/EA004632B1/en not_active IP Right Cessation
- 2000-05-31 CA CA002375551A patent/CA2375551A1/en not_active Abandoned
- 2000-05-31 EE EEP200100673A patent/EE200100673A/en unknown
- 2000-05-31 HU HU0202508A patent/HUP0202508A3/en unknown
- 2000-05-31 OA OA1200100327A patent/OA11963A/en unknown
- 2000-05-31 JP JP2001502823A patent/JP2003504310A/en active Pending
- 2000-05-31 BR BR0011728-5A patent/BR0011728A/en not_active IP Right Cessation
- 2000-05-31 AU AU54553/00A patent/AU775157B2/en not_active Ceased
- 2000-05-31 SK SK1763-2001A patent/SK17632001A3/en unknown
- 2000-05-31 KR KR1020017015879A patent/KR20020008224A/en not_active Application Discontinuation
- 2000-05-31 MX MXPA01012318A patent/MXPA01012318A/en not_active Application Discontinuation
- 2000-05-31 DZ DZ003252A patent/DZ3252A1/fr active
- 2000-05-31 AP APAP/P/2002/002387A patent/AP2002002387A0/en unknown
- 2000-05-31 PL PL00352430A patent/PL352430A1/en not_active Application Discontinuation
-
2001
- 2001-11-28 ZA ZA200109794A patent/ZA200109794B/en unknown
- 2001-12-07 CR CR6528A patent/CR6528A/en not_active Application Discontinuation
- 2001-12-07 IS IS6193A patent/IS6193A/en unknown
- 2001-12-07 NO NO20015995A patent/NO20015995L/en not_active Application Discontinuation
-
2002
- 2002-01-02 MA MA26463A patent/MA26805A1/en unknown
- 2002-01-09 BG BG106293A patent/BG106293A/en unknown
- 2002-01-10 HR HR20020026A patent/HRP20020026A2/en not_active Application Discontinuation
-
2003
- 2003-01-16 HK HK03100404.7A patent/HK1048258A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA004632B1 (en) | 2004-06-24 |
MXPA01012318A (en) | 2002-07-22 |
IS6193A (en) | 2001-12-07 |
EA200101135A1 (en) | 2002-06-27 |
WO2000076489A3 (en) | 2002-05-30 |
CR6528A (en) | 2004-02-23 |
AU5455300A (en) | 2001-01-02 |
GEP20053423B (en) | 2005-01-25 |
JP2003504310A (en) | 2003-02-04 |
DZ3252A1 (en) | 2000-12-21 |
MA26805A1 (en) | 2004-12-20 |
OA11963A (en) | 2006-04-17 |
EE200100673A (en) | 2003-02-17 |
IL146971A0 (en) | 2002-08-14 |
EP1225886A2 (en) | 2002-07-31 |
HRP20020026A2 (en) | 2003-08-31 |
SK17632001A3 (en) | 2003-03-04 |
PL352430A1 (en) | 2003-08-25 |
KR20020008224A (en) | 2002-01-29 |
CA2375551A1 (en) | 2000-12-21 |
WO2000076489A2 (en) | 2000-12-21 |
BR0011728A (en) | 2002-02-26 |
TR200103551T2 (en) | 2002-12-23 |
NO20015995D0 (en) | 2001-12-07 |
BG106293A (en) | 2002-06-28 |
CN1378446A (en) | 2002-11-06 |
HK1048258A1 (en) | 2003-03-28 |
HUP0202508A3 (en) | 2003-03-28 |
AP2002002387A0 (en) | 2002-03-31 |
NZ515621A (en) | 2004-05-28 |
NO20015995L (en) | 2002-02-04 |
AU775157B2 (en) | 2004-07-22 |
YU86701A (en) | 2004-09-03 |
ZA200109794B (en) | 2003-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0202508A2 (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | |
JP2004518725A5 (en) | ||
HUP0300318A2 (en) | Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use | |
HUP0500173A2 (en) | Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them | |
HUP0301857A2 (en) | 3(5)-ureido-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
CY1108019T1 (en) | Pyrimidine compounds | |
HUP0301195A2 (en) | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists and pharmaceutical compositions containing the compounds | |
HUP0201935A2 (en) | Purine derivatives inhibitors of tyrosine protein kinase syk | |
HUP9904693A2 (en) | Inhibition of 26s and 20s proteasome by indanones | |
DK0590919T3 (en) | Therapeutic agents for Parkinson's disease | |
CY1107108T1 (en) | ARYLOMETHYL-CARBONYLAMINE-THIAZOLIS PRODUCERS AND USE AS ANTI-PLASTIC FACTORS | |
RU2007106180A (en) | Derivatives of indole, indazole or indoline | |
HUP0203228A2 (en) | Substituted indoles for modulating nfkb activity, process for their preparation and pharmaceutical compositions containing them and their use | |
RU2007108861A (en) | TRIFTOMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | |
HUP9701193A2 (en) | Use of n-(4-aryl-thiazol-2-yl)-sulfonamide derivatives for the preparation of pharmaceutical compositions treating neurological disorders, new derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0301493A2 (en) | Indole derivatives, process for preparation of the same and use thereof | |
HUP0100615A2 (en) | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and their use to reduce tnfalpha levels | |
HUP0203448A2 (en) | Biaryl ether derivatives useful as monoamine reuptake inhibitors and pharmaceutical compositions containing them | |
MY119238A (en) | 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
HUP0202593A2 (en) | Benzophenones as inhibitors of reverse transcriptase | |
HUP9902148A2 (en) | Novel 2,3 disubstituted-4(3h)-quinazolinones | |
SE9702799D0 (en) | New compounds | |
HUP0500111A2 (en) | Indolinone derivatives useful as protein kinase inhibitors | |
ATE517625T1 (en) | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | |
HUP0303272A2 (en) | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators, pharmaceutical compositions containing them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |